OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-r...
A director at Banc Of California Inc bought 14,000 shares at 21.120USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...
Allied Gaming and Entertainment Issues Statement to Shareholders and the Investment Community Company Reaffirms Financial Strength, Strategic Progress and Long-Term Confidence Amid Elevated Short-Selling Activity New York, Dec. 05, 2025 (GLOBE NEWSWIRE) -- NEW YORK, NY — December 5, 2025 — Allied Gaming & Entertainment Inc. (NASDAQ: AGAE) (the “Company”) today issued a statement to shareholders and the investment community regarding recent market activity and to reinforce management’s confidence in the Company’s financial position and strategic outlook. The Company has observed unusu...
A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30, 2025, the Company announced that its Board of Directors determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a compr...
AGAE Completes Acquisition of Leading Japanese Vocational High School, Advancing Global Education Expansion Strategy Tokyo, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tokyo, Japan – November 10, 2025 – Allied Gaming & Entertainment Inc. (“Allied” or the “Company”), a global experiential entertainment and gaming company, is pleased to announce that it has officially completed the acquisition of Saiju School. Founded in 1943, Saiju School is the No. 1 Higher Vocational School (Higher Vocational School Course) accredited by Shiga Prefecture, Japan. This acquisition marks Allied’s formal entry into Ja...
Allied Gaming and Entertainment Showcases Growth with Proprietary Live Events at HyperX Arena Las Vegas Las Vegas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- New York – October 29, 2025 – Allied Gaming & Entertainment Inc. (NASDAQ: AGAE) (“Allied” or the “Company”), a global experiential entertainment company, celebrates two major events—one recently hosted and one upcoming—at its flagship property, Allied Esports’ HyperX Arena Las Vegas, underscoring the Company’s continued leadership in live entertainment, esports, and global event production. World Esports Day Celebration Unites the Las Vegas...
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors has determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximizi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.